The bile acid-activated farnesoid X receptor (FXR, NR1H4) has emerged as a promising therapeutic target[3], [4], [5] as it orchestrates key processes that may counteract or at least ameliorate cholestasis. The gene discussed is NR1H4; the disease is cholestasis.